Page last updated: 2024-12-08
jmv 179
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
JMV 179: cholecystokinin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 164107 |
MeSH ID | M0191065 |
Synonyms (10)
Synonym |
---|
jmv 179 |
119386-87-7 |
l-aspartic acid, n-(n-(n-(n-(n-(n-((1,1-dimethylethoxy)carbonyl)-o-sulfo-l-tyrosyl)-l-norleucyl)glycyl)-d-tryptophyl)-l-norleucyl)-, 1-(2-phenylethyl) ester |
tert-butoxycarbonyl-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartic acid phenethyl ester |
jmv-179 |
tert butoxycarbonyl-sulfo-tyrosyl-norleucyl-glycyl-tryptophyl-norleucyl-aspartic acid phenethyl ester |
boc-tyr(so3h)-nle-gly-trp-nle-asp-o-ch2-ch2-c6h5 |
(6s,9s,15r,18s,21s)-15-((1h-indol-3-yl)methyl)-9,18-dibutyl-2,2-dimethyl-4,7,10,13,16,19-hexaoxo-21-(phenethoxycarbonyl)-6-(4-(sulfooxy)benzyl)-3-oxa-5,8,11,14,17,20-hexaazatricosan-23-oic acid |
(3s)-3-[[(2s)-2-[[(2r)-3-(1h-indol-3-yl)-2-[[2-[[(2s)-2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxo-4-(2-phenylethoxy)butanoic acid |
AKOS040745896 |
Research Excerpts
Actions
Excerpt | Reference | Relevance |
---|---|---|
"JMV 179 tended to increase the latency of the passive avoidance response upon retention testing at the 24th hour but not on the 7th day after training." | ( Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179. Hadjiivanova, C; Kehayov, R; Martinez, J; Petkov, VV, 1994) | 1.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (85.71) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |